糠酸氟替卡松/维兰特罗复方剂治疗哮喘疗效与耐受性的Meta分析

Efficacy and safety of fluticasone furoate/vilanterol in patients with asthma:a systematic review by Meta-analysis

目的 比较糠酸氟替卡松/维兰特罗复方剂(FF/VI)与吸入型糖皮质激素单药或联合长效β2受体激动剂治疗哮喘患者的疗效与耐受性差异.方法 计算机检索CNKI、PubMed、Embase、Cochrane Library等数据库,纳入随机对照试验,采用Cochrane系统评价方法进行评价.结果 共纳入10个研究,共9811例患者.在疗效上,FF/VI组与对照组相比,提高患者的1秒用力呼气量谷值[WMD=0.09,95%CI(0.05,0.13),P=0.000]和哮喘控制测试评分[WMD=0.63,95%CI(0.24,1.03),P=0.002].在耐受性方面,FF/VI组与对照组相比不增加患者发生与治疗相关不良反应事件风险[RR=1.15,95%CI(0.98,1.36),P=0.000].结论 用FF/VI治疗哮喘在疗效方面具有优势,且具有良好的耐受性.其每日1次的用药频次可提高患者依从性,值得推荐使用.

Objective To evaluate the efficacy and safety of once-daily fluticasone furoate/vilanterol compared with ICS alone or twice-daily ICS/LABA formulations in patients with asthma.Methods Systematic search was performed for randomized controlled trials in the CNKI,PubMed,Embase and Cochrane Library.Results 10 citations contained 9 811 patients with asthma met the selection criteria.In terms of efficacy,compared with the control group,the patient′s trough forced expiratory volume in one second[WMD= 0.09,95% Cl(0.05,0.13)P=0.000]and asthma control Test score[WMD= 0.63,95% CI(0.24,1.03),P=0.002]were increased in the FF/VI group.In terms of safety,the risk of adverse reaction events associated with treatment in patients was not increased in the FF/VI group compared to the control group[RR=1.15,95% CI(0.98,1.36),P= 0.000].Conclusion FF/VI had advantages and better tolerance in treating asthma patients.It is recommended to be used for its once-daily use of the frequency,which was the advantage of improving patient adherence.